Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
16 hedge funds and large institutions have $1.3M invested in Petros Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.02% → 0.02% (-0.01%)
11% less funds holding
Funds holding: 18 → 16 (-2)
11% less call options, than puts
Call options by funds: $112K | Put options by funds: $126K
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
64% less capital invested
Capital invested by funds: $3.58M → $1.3M (-$2.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$290K |
| 2 |
Two Sigma Investments
New York
|
+$175K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$116K |
| 4 |
Two Sigma Advisers
New York
|
+$104K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.14M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$190K |
| 3 |
VF
Virtu Financial
New York
|
-$177K |
| 4 |
Squarepoint
New York
|
-$119K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$114K |
PTPI Hedge Fund Activity: Q1 2022 in Review
16 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q1 2022, worth a combined $1.3M — down 64% from $3.58M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PTPI and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was BlackRock, adding an estimated $290K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $1.14M sold.
- 16 institutional investors held Petros Pharmaceuticals (PTPI) as of Q1 2022, down from 18 in Q4 2021.
- Funds reported $1.3M of Petros Pharmaceuticals stock for Q1 2022, down 64% quarter-over-quarter.
- 4 funds opened new Petros Pharmaceuticals positions in Q1 2022 and 6 closed out, a net change of -2 holders.
- The largest Petros Pharmaceuticals buyer in Q1 2022 was BlackRock, an estimated $290K added.
- The largest Petros Pharmaceuticals seller in Q1 2022 was Schonfeld Strategic Advisors, an estimated $1.14M sold.
Based on aggregated 13F filings for Q1 2022.